Literature DB >> 11496329

Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas.

Y W Kim1, S H Huh, Y K Park, T Y Yoon, S M Lee, S H Hong.   

Abstract

Gallbladder carcinoma is the most common malignancy of the biliary tract in Korea and known to be more common in East Asia and Latin America than in Europe and North America. However, their exact histopathological characteristics and carcinogenesis are not well-elucidated. A total of 71 cases of gallbladder carcinomas, two cases of gallbladder dysplasia and 20 cases of gallbladder adenoma were immunohistochemically studied to evaluate the expression of c-erb-B2 and p53 proteins in the light of their relationship with various prognostic factors. Thirty-three gallbladder carcinomas (46.5%) showed positive staining for c-erb-B2, but none of the dysplasia and adenoma were positive (p<0.05). c-erb-B2 was stained in the cell membrane of the cancer cells. Adjacent normal mucosa was negative for c-erb-B2 staining. Forty-eight gallbladder carcinomas (67.6%) showed positive staining in the nucleus for p53 protein. None of the cases with dysplasia, adenoma, and normal mucosa stained positive for p53 protein. There was no significant correlation between c-erb-B2 and p53 expression and age, gender, histological tumor grade, and tumor stage. In the multivariate analysis, tumor stage approached statistical significance (p=0.05), but c-erb-B2 and p53 expression was not significant (p=0.14 and p=0.29, respectively). The mean survival periods of the c-erb-B2 positive and negative groups were 26 months and 52 months, respectively (p=0.02). However, the mean survival periods of the p53 protein positive and negative patients were 34 months and 35 months, respectively (p=0.45). In conclusion, our results suggest that c-erb-B2 and p53 protein expression is strongly associated with neoplastic progression in gallbladder carcinomas, and that c-erb-B2 expression identifies patients with a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496329     DOI: 10.3892/or.8.5.1127

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  Expression of cell cycle-related proteins, p16, p53 and p63 as important prognostic markers in gallbladder adenocarcinoma.

Authors:  Kyungeun Kim; Dong-Hoon Kim; Seoung Wan Chae; Jun-Ho Shin; Hong Joo Kim; Sung-Im Do; Hyun Joo Lee; Ji Hae Koo; Jung-Soo Pyo; Jin Hee Sohn
Journal:  Pathol Oncol Res       Date:  2013-11-01       Impact factor: 3.201

2.  Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt; Andrej Cor
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.

Authors:  Hiroshi Yoshida; Kazuaki Shimada; Tomoo Kosuge; Nobuyoshi Hiraoka
Journal:  Virchows Arch       Date:  2016-01-13       Impact factor: 4.064

4.  Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

Authors:  Iván Roa; Gonzalo de Toro; Kurt Schalper; Xabier de Aretxabala; Chaitanya Churi; Milind Javle
Journal:  Gastrointest Cancer Res       Date:  2014-03

5.  Expression of HER2 and bradykinin B₁ receptors in precursor lesions of gallbladder carcinoma.

Authors:  Cesar Toledo; Carola E Matus; Ximena Barraza; Pamela Arroyo; Pamela Ehrenfeld; Carlos D Figueroa; Kanti D Bhoola; Maeva Del Pozo; Maria T Poblete
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 6.  Gallbladder cancer: Clinical and pathological approach.

Authors:  Keita Kai; Shinichi Aishima; Kohji Miyazaki
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337

7.  The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.

Authors:  Takuya Kitamura; Kevin Connolly; Lynnsie Ruffino; Tetsuo Ajiki; Aline Lueckgen; John DiGiovanni; Kaoru Kiguchi
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

8.  Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas.

Authors:  Hee Jin Chang; Byong Chul Yoo; Sun Whe Kim; Byung Lan Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.

Authors:  Toru Kawamoto; Savitri Krishnamurthy; Emily Tarco; Smita Trivedi; Ignacio I Wistuba; Donghui Li; Ivan Roa; Juan C Roa; Melanie B Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-11

10.  Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers.

Authors:  Luis A Hidalgo Grau; Josep M Badia; Carmen Admella Salvador; Teresa Soler Monsó; Josep Feliu Canaleta; Josep M Gubern Nogués; Javier Suñol Sala
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.